Human CCR8 Stable Cell Line - CT26

CCR8 (C-C Chemokine Receptor Type 8) is a seven-transmembrane G protein-coupled receptor primarily expressed on regulatory T cells (Tregs), Th2 cells, and certain tumor-infiltrating lymphocytes. Its ligand CCL1/I-309 drives Treg migration, immunosuppression, and tumor immune evasion, making CCR8 an emerging therapeutic target in cancer immunotherapy. The Human CCR8 Stable Cell Line - CT26 is a genetically engineered murine colon carcinoma cell line that stably expresses full-length human CCR8 on the cell surface. This cell line is generated by transfecting the human CCR8 gene into parental CT26 cells followed by antibiotic selection and clonal isolation, ensuring consistent and high-level receptor expression over multiple passages. The stable expression of human CCR8 in a murine background provides a physiologically relevant model for studying receptor biology, ligand-receptor interactions, and downstream signaling in a tumor microenvironment context.

The Human CCR8 Stable Cell Line - CT26 is widely used in preclinical drug discovery and immunotherapy development. It serves as a valuable tool for screening and characterizing CCR8-targeting antibodies, small molecule antagonists, and chimeric antigen receptor (CAR)-T cell therapeutics. Researchers can employ this cell line in functional assays such as calcium flux, chemotaxis, and β-arrestin recruitment to evaluate compound potency and selectivity. In particular, the cell line is instrumental for testing the efficacy of anti-CCR8 CAR-T cells in vitro, where target-specific cytotoxicity and cytokine release can be accurately measured. Additionally, when implanted into immunocompetent syngeneic mouse models, the CCR8-expressing CT26 line enables in vivo assessment of anti-tumor immune responses, tumor infiltration dynamics, and therapeutic efficacy. This stable cell line thus bridges the gap between early target validation and translational immunotherapy research, supporting both mechanistic studies and lead optimization in the development of next-generation cancer treatments.